Insight Molecular Diagnostics Prices $15 Million Offering While Its Transplant Test Awaits FDA Authorization
The company expects about $14 million after fees and expenses as it works to answer the FDA's concerns about GraftAssureDx.
Insight Molecular Diagnostics, which develops molecular tests to monitor transplanted organ rejection, priced a $15 million offering Tuesday at $1.75 per common share, about 6% below Monday's $1.86 reference close. The prospectus supplement, filed Wednesday, puts the new common shares at about 20% of shares outstanding after the offering, assuming full exercise of the pre-funded warrants.
New Shares And $14 Million Net
The offering includes 8,296,429 common shares and pre-funded warrants covering up to 275,000 more. With those warrants fully exercised, the company would have 41,326,919 shares outstanding after the offering.
The company estimates about $14 million in proceeds after underwriting charges and offering expenses. Its stated use is "general working capital and corporate purposes, including but not limited to research and development in the transplantation category," according to the proceeds allocation.
Lake Street Capital Markets, the sole underwriter selling the securities, has a 30-day option to buy up to 1,285,714 additional common shares. Full exercise would bring estimated net proceeds to about $16 million. Certain directors and officers agreed to buy 28,571 shares at the public offering price, totaling approximately $50,000.
The company launched the offering Monday. IMDX shares were $1.78 at Tuesday's close.
Transplant Kits Drive The Business
Insight's transplant business spans laboratory testing and kits that customers can run themselves. Medicare reimburses GraftAssureCore testing at its Franklin, Tennessee laboratory; GraftAssureIQ kits are for research use. GraftAssureDx is being developed for clinical testing in local laboratories, with kidney transplants the initial focus for regulatory authorization.
The GraftAssure tests use instruments made by Bio-Rad Laboratories, its partner in developing and commercializing clinical transplant kits. The assays have reached 22 sites in eight countries across three continents, in research, pilot or clinical-trial settings.
Insight also provides test-development and clinical-testing services to life sciences and biotechnology companies. It reported third-quarter revenue of $559,000 and attributed lower operating expenses to winding down FDA-submission costs.
FDA Questions Still Need Answers
Insight submitted GraftAssureDx for FDA authorization on March 25, 2026. An FDA letter on July 25 identified deficiencies and put the application on hold. The agency's preliminary assessment was that the clinical evidence did not yet support the proposed use.
The concerns primarily involved clinical-study design and analysis, alongside analytical testing, software and third-party components. At a September 29 meeting, Insight sought feedback on its response, including a narrower intended use.
Written FDA feedback received October 30 raised questions about combining existing and additional clinical data, the timing of a revised analysis plan and the proposed sensitivity goal. The agency also indicated that clinical data may be necessary for parent and child donors. Insight believes it can supply sufficient additional evidence, but authorization remains pending.
Insight expects to submit a complete response before January 21, 2027. Without a complete response by that deadline, the FDA would consider the application withdrawn, requiring a new submission.
Sources
- Form 424B5 — Insight Molecular Diagnostics Inc. (IMDX) — SEC EDGAR
- https://www.sec.gov/Archives/edgar/data/1642380/000149315226052499/form424b5.htm — sec.gov
- Insight Molecular Diagnostics Inc. Form 10-Q for the period ended September 30, 2026 — sec.gov
- Insight Molecular Diagnostics Announces Pricing of $15 — globenewswire.com
- Insight Molecular Diagnostics Announces Proposed Public — globenewswire.com
- IMDx Reports Third Quarter 2026 Results and Provides — globenewswire.com